Understand the words
A weight-care plan needs a product name.
When this comes up
You are comparing weight-care pages. One names a drug, another says compounded, and another calls its option the next new thing.
Ask for the exact product and form. Keep an approved drug, a made-to-order preparation, and a product still under study separate in your notes.
Start with what is approved
As of September 26, 2026, semaglutide (Wegovy) has FDA-approved weight-care tablet and injection products.
As of September 26, 2026, tirzepatide (Zepbound) is an FDA-approved injection for long-term weight management.
Ask the person treating you how the exact label relates to your health history and the reason for the visit.
Do not stretch a shortage claim
FDA’s national drug shortage list, as of September 26, 2026, has no listing for semaglutide injections or for tirzepatide.
Compounded means a medicine is made to order. Ask the person writing the prescription, 'Why is this version allowed to be made for me under federal law?' Ask them to explain the rule in plain words and put the answer in writing.
As of September 26, 2026, FDA states that using retatrutide or cagrilintide in compounding is forbidden by federal law.
As of September 26, 2026, retatrutide has no US drug approval.
Ask whether the exact medicine is approved now and which government record shows that. A prediction about future approval does not answer that question.